[Form 4] Cocrystal Pharma, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Cocrystal Pharma (COCP) reported an insider purchase by a senior officer. On 10/28/2025, the reporting person acquired 3,598 shares of common stock at $1.39 per unit, with each unit also including warrants to buy two shares. The filing also shows acquisition of 7,196 warrants with a $1.24 exercise price, exercisable upon issuance and expiring on 01/28/2028. Following the transactions, beneficial ownership stands at 44,167 shares held directly, which includes shares issuable upon vesting of restricted stock units.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Martin James Joseph

(Last) (First) (Middle)

4400 BISCAYNE BLVD

SUITE # 670

(Street)

MIAMI FL 33157

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cocrystal Pharma, Inc. [ COCP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-CEO and CFO

3. Date of Earliest Transaction (Month/Day/Year)
10/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	10/28/2025		A		3,598	A	$1.39	44,167(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants(1)	$1.24	10/28/2025		A		7,196		(1)	01/28/2028	Common Stock	7,196	$1.39	7,196	D

Explanation of Responses:

1. The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock. The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance.

2. Includes shares of common stock issuable upon vesting of restricted stock units.

	/s/ James Martin	10/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did COCP disclose?

An officer acquired 3,598 shares at $1.39 per unit and 7,196 warrants exercisable at $1.24.

When did the COCP insider transaction occur?

The transaction date was 10/28/2025.

What are the terms of the COCP warrants?

The warrants are exercisable upon issuance at $1.24 and expire on 01/28/2028.

How many COCP shares does the insider own after the transaction?

Beneficial ownership is 44,167 shares held directly, including shares issuable upon RSU vesting.

What was included in each COCP unit purchased?

Each unit comprised one common share plus a warrant to purchase two additional shares.

Was the transaction approved for Rule 16b-3 exemption?

Yes. It was approved by a Special Committee of two non-employee directors, qualifying under Rule 16b-3.